My child is unique; The pharmacokinetics are universal

Paediatric Anaesthesia

Volumn 22, Issue 6, 2012, Pages 530-538

  Anderson, Brian J ^a  

^a STARSHIP CHILDREN S HOSPITAL   (New Zealand)

Author keywords

adverse effects; children; pharmacodynamics; pharmacokinetics; pharmacology

Indexed keywords

BUPIVACAINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; FENTANYL; GLUCURONOSYLTRANSFERASE 1A6; KETAMINE; MIDAZOLAM; MORPHINE; OXYHEMOGLOBIN; PARACETAMOL; PROPOFOL; TETRACYCLINE; TRAMADOL;

AMNESIA; APOPTOSIS; BODY SIZE; BODY SURFACE; BODY WEIGHT; CARDIOTOXICITY; CIRCADIAN RHYTHM; ELIMINATION REACTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTHYROIDISM; LEAN BODY WEIGHT; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TOOTH DISCOLORATION; VOMITING;

AGING; ANESTHESIA; ANESTHETICS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; DISEASE; DRUG INTERACTIONS; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; INFANT, NEWBORN; MODELS, STATISTICAL; PHARMACOGENETICS;

EID: 84861341423     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2011.03788.x     Document Type: Review

References (102)

1. Gobburu JV, Holford NH,. Vz, the terminal phase volume: time for its terminal phase? J Biopharm Stat 2001; 11: 373-375.
2. Holford NH,. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287-291.
3. Holford NH,. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 55S-59S.
4. Edginton AN,. Knowledge-driven approaches for the guidance of first-in-children dosing. Pediatr Anesth 2011; 21: 206-213.
5. Johnson TN, Rostami-Hodjegan A,. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatr Anesth 2011; 21: 291-301.
6. Alcorn J, McNamara PJ,. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 2002; 41: 1077-1094.
7. Alcorn J, McNamara PJ,. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41: 959-998.
8. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
9. Holford NH, Ma SC, Anderson BJ,. Prediction of morphine dose in humans. Pediatr Anesth 2011; doi: 10.1111/j.1460-9592.2011.03782.x [Epub ahead of print].
10. Sepulveda P, Cortinez LI, Saez C, et al. Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children. Br J Anaesth 2011; 107: 593-600.
11. Benet LZ,. A Holy Grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient. Clin Pharmacol Ther 2009; 86: 133-134.
12. Anderson BJ, Hodkinson B,. Are there still limitations for the use of target-controlled infusion in children? Curr Opin Anaesthesiol 2010; 23: 356-362.
13. Tod M, Jullien V, Pons G,. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-243.
14. Lack JA, Stuart Taylor ME,. Calculation of drug dosage and body surface area of children. Br J Anaesth 1997; 78: 601-605.
15. Sumpter AL, Holford NH,. Predicting weight using postmenstrual age-neonates to adults. Pediatr Anesth 2011; 21: 309-315.
16. Anderson BJ, Meakin GH,. Scaling for size: some implications for paediatric anaesthesia dosing. Pediatr Anesth 2002; 12: 205-219.
17. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
18. Du Bois D, Du Bois EF,. Clinical calorimetry: tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-871.
19. James W,. Research on Obesity. London: Her Majesty's Stationary Office, 1976.
20. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-1065.
21. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2008; 24: 67-76.
22. West GB, Brown JH,. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 2005; 208: 1575-1592.
23. Potts AL, Larsson P, Eksborg S, et al. Clonidine disposition in children; a population analysis. Pediatr Anesth 2007; 17: 924-933.
24. Anderson BJ, van Lingen RA, Hansen TG, et al. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 2002; 96: 1336-1345.
25. Herd D, Anderson BJ,. Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. Pediatr Anesth 2007; 17: 622-629.
26. Chalkiadis GA, Anderson BJ,. Age and size are the major covariates for prediction of levobupivacaine clearance in children. Pediatr Anesth 2006; 16: 275-282.
27. Allegaert K, van den Anker JN, de Hoon JN, et al. Covariates of tramadol disposition in the first months of life. Br J Anaesth 2008; 100: 525-532.
28. Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007; 29: 284-291.
29. Oshikoya KA, Sammons HM, Choonara I,. A systematic review of pharmacokinetics studies in children with protein-energy malnutrition. Eur J Clin Pharmacol 2010; 66: 1025-1035.
30. Mulla H, Johnson TN,. Dosing dilemmas in obese children. Arch Dis Child Educ Pract Ed 2010; 95: 112-117.
31. Mortensen A, Lenz K, Abildstrom H, et al. Anesthetizing the obese child. Pediatr Anesth 2011; 21: 623-629.
32. Cortinez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth 2010; 105: 448-456.
33. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562-573.
34. Gaszynski T, Strzelczyk J, Machala W, et al. Reduction of a total propofol consumption in morbidly obese patients during general anesthesia due to BIS monitoring. Obes Surg 2005; 15: 1084; author reply 1085.
35. Hill AV,. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910; 14: iv-vii.
36. Welzing L, Ebenfeld S, Dlugay V, et al. Remifentanil degradation in umbilical cord blood of preterm infants. Anesthesiology 2011; 114: 570-577.
37. Saarenmaa E, Neuvonen PJ, Fellman V,. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J Pediatr 2000; 136: 767-770.
38. Allegaert K, Palmer GM, Anderson BJ,. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011; 96: 575-580.
39. Anderson BJ, Pons G, Autret-Leca E, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Pediatr Anesth 2005; 15: 282-292.
40. Chan RA, Benner EJ, Hoeprich PD,. Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med 1972; 76: 773-778.
41. Dettli LC,. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974; 16: 274-280.
42. Sarubbi FA Jr, Hull JH,. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med 1978; 89: 612-618.
43. Sirinavin S, McCracken GH Jr, Nelson JD,. Determining gentamicin dosage in infants and children with renal failure. J Pediatr 1980; 96: 331-334.
44. Yoshioka H, Takimoto M, Matsuda I, et al. Dosage schedule of gentamicin for chronic renal insufficiency in children. Arch Dis Child 1978; 53: 334-337.
45. Pokela ML, Olkkola KT, Seppala T, et al. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20: 26-34.
46. Peters JW, Anderson BJ, Simons SH, et al. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006; 45: 705-714.
47. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101: 680-689.
48. Koehntop DE, Rodman JH, Brundage DM, et al. Pharmacokinetics of fentanyl in neonates. Anesth Analg 1986; 65: 227-232.
49. Kuhls E, Gauntlett IS, Lau M, et al. Effect of increased intra-abdominal pressure on hepatic extraction and clearance of fentanyl in neonatal lambs. J Pharmacol Exp Ther 1995; 274: 115-119.
50. Williams DG, Hatch DJ, Howard RF,. Codeine phosphate in paediatric medicine. Br J Anaesth 2001; 86: 413-421.
51. Williams DG, Patel A, Howard RF,. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 2002; 89: 839-845.
52. Collins SL, Moore RA, McQuay HJ, et al. Single dose oral ibuprofen and diclofenac for postoperative pain. Cochrane Database Syst Rev 2000; 2: CD001548.
53. Neville KA, Becker ML, Goldman JL, et al. Developmental pharmacogenomics. Pediatr Anesth 2011; 21: 255-265.
54. Daly AK,. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010; 11: 607-611.
55. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
56. Daly AK,. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004; 4: 1733-1744.
57. Fishbain DA, Fishbain D, Lewis J, et al. Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. Pain Med 2004; 5: 81-93.
58. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-2279.
59. Becquemont L, Alfirevic A, Amstutz U, et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011; 12: 113-124.
60. Galinkin JL, Demmer L, Yaster M,. Genetics for the pediatric anesthesiologist: a primer on congenital malformations, pharmacogenetics, and proteomics. Anesth Analg 2010; 111: 1264-1274.
61. Mertens MJ, Olofsen E, Burm AG, et al. Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. Anesthesiology 2004; 100: 795-805.
62. Vuyk J, Lichtenbelt BJ, Olofsen E, et al. Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. Anesth Analg 2009; 108: 1522-1530.
63. Vuyk J,. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. Acta Anaesthesiol Belg 2001; 52: 445-451.
64. Corcos L, Lagadic-Gossmann D,. Gene induction by Phenobarbital: an update on an old question that receives key novel answers. Pharmacol Toxicol 2001; 89: 113-122.
65. Eker HE, Yalcin Cok O, Aribogan A, et al. Children on phenobarbital monotherapy requires more sedatives during MRI. Pediatr Anesth 2011; 21: 998-1002.
66. Sumpter A, Anderson BJ,. Phenobarbital and some anesthesia implications. Pediatr Anesth 2011; 21: 995-997.
67. Cappellini MD, Fiorelli G,. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371: 64-74.
68. Gal P, Gilman JT,. Drug disposition in neonates with patent ductus arteriosus. Ann Pharmacother 1993; 27: 1383-1388.
69. Rabbitts JA, Groenewald CB, Dietz NM, et al. Perioperative opioid requirements are decreased in hypoxic children living at altitude. Pediatr Anesth 2010; 20: 1078-1083.
70. Waters KA, McBrien F, Stewart P, et al. Effects of OSA, inhalational anesthesia, and fentanyl on the airway and ventilation of children. J Appl Physiol 2002; 92: 1987-1994.
71. Henthorn TK, Liu Y, Mahapatro M, et al. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 1999; 289: 1084-1089.
72. Hamabe W, Maeda T, Kiguchi N, et al. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J Pharmacol Sci 2007; 105: 353-360.
73. Peeters MY, Prins SA, Knibbe CA, et al. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 2006; 104: 466-474.
74. Potts AL, Cheeseman JF, Warman GR,. Circadian rhythms and their development in children: implications for pharmacokinetics and pharmacodynamics in anesthesia. Pediatr Anesth 2011; 21: 238-246.
75. Van Boxtel C, Holford N, Danhof M,. In Vivo Study of Drug Action. Amsterdam: Elsevier, 1992.
76. Lerman J,. Pharmacology of inhalational anaesthetics in infants and children. Pediatr Anesth 1992; 2: 191-203.
77. LeDez KM, Lerman J,. The minimum alveolar concentration (MAC) of isoflurane in preterm neonates. Anesthesiology 1987; 67: 301-307.
78. Tsuruta S, Satsumae T, Mizutani T, et al. Minimum alveolar concentrations of sevoflurane for maintaining bispectral index below 50 in children. Pediatr Anesth 2011; 21: 1124-1127.
79. Lerman J, Robinson S, Willis MM, et al. Anesthetic requirements for halothane in young children 0-1 month and 1-6 months of age. Anesthesiology 1983; 59: 421-424.
80. Yu L, Sun H, Yao L, et al. Comparison of effective inspired concentration of sevoflurane in preterm infants with different postconceptual ages. Pediatr Anesth 2011; 21: 148-152.
81. Koch SC, Fitzgerald M, Hathway GJ,. Midazolam potentiates nociceptive behavior, sensitizes cutaneous reflexes, and is devoid of sedative action in neonatal rats. Anesthesiology 2008; 108: 122-129.
82. Choudhuri S, Klaassen CD,. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231-259.
83. Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43: 983-1013.
84. Rollason V, Samer C, Piguet V, et al. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008; 9: 905-933.
85. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology 2004; 101: 279-283.
86. Cunningham AL, Jones CP, Ansell J, et al. Red for danger: the effects of red hair in surgical practice. BMJ 2010; 341: c6931.
87. Long LS, Ved S, Koh JL,. Intraoperative opioid dosing in children with and without cerebral palsy. Pediatr Anesth 2009; 19: 513-520.
88. Valkenburg AJ, de Leeuw TG, Tibboel D, et al. Lower bispectral index values in children who are intellectually disabled. Anesth Analg 2009; 109: 1428-1433.
89. Gras S, Servin F, Bedairia E, et al. The effect of preoperative heart rate and anxiety on the propofol dose required for loss of consciousness. Anesth Analg 2010; 110: 89-93.
90. Fredriksson A, Archer T, Alm H, et al. Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav Brain Res 2004; 153: 367-376.
91. Wang C, Sadovova N, Fu X, et al. The role of the N-methyl-D-aspartate receptor in ketamine-induced apoptosis in rat forebrain culture. Neuroscience 2005; 132: 967-977.
92. Davidson AJ,. Anesthesia and neurotoxicity to the developing brain: the clinical relevance. Pediatr Anesth 2011; 21: 716-721.
93. Litman RS, Soin K, Salam A,. Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications. Anesth Analg 2010; 110: 739-746.
94. Kiuchi MG, Zapata-Sudo G, Trachez MM, et al. The influence of age on bupivacaine cardiotoxicity. Anesth Analg 2011; 112: 574-580.
95. Anderson BJ, Ralph CJ, Stewart AW, et al. The dose-effect relationship for morphine and vomiting after day-stay tonsillectomy in children. Anaesth Intensive Care 2000; 28: 155-160.
96. Weinstein MS, Nicolson SC, Schreiner MS,. A single dose of morphine sulfate increases the incidence of vomiting after outpatient inguinal surgery in children. Anesthesiology 1994; 81: 572-577.
97. Bouillon T, Bruhn J, Radu-Radulescu L, et al. A model of the ventilatory depressant potency of remifentanil in the non-steady state. Anesthesiology 2003; 99: 779-787.
98. Standing JF, Hammer GB, Sam WJ, et al. Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. Pediatr Anesth 2011; 20: 7-18.
99. Welzing L, Kribs A, Eifinger F, et al. Propofol as an induction agent for endotracheal intubation can cause significant arterial hypotension in preterm neonates. Pediatr Anesth 2010; 20: 605-611.
100. Vanderhaegen J, Naulaers G, Van Huffel S, et al. Cerebral and systemic hemodynamic effects of intravenous bolus administration of propofol in neonates. Neonatology 2010; 98: 57-63.
101. Lerman J, Heard C, Steward DJ,. Neonatal tracheal intubation: an imbroglio unresolved. Pediatr Anesth 2010; 20: 585-590.
102. Allegaert K, Anderson BJ, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth 2005; 95: 231-239.